Welcome to OncoAssure!

OncoAssure is a new medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.

OncoAssure’s lead product in development is a post-biopsy test for prostate cancer that measures the expression of genes that are key drivers of cancer progression. This test will accurately identify patients with less aggressive disease who can confidently avoid aggressive therapies. The test utilises the OncoAssure process to identify key drivers of cancer progression. This process has been previously applied in the successful development of a prognostic test for breast cancer recurrence and can be applied in other cancers where significant unmet needs also exist.

The OncoAssure team have the key skills, expertise, and a proven track record in identifying, developing, and commercialising cancer biomarkers. The team previously developed the OncoMasTR breast cancer prognostic test at OncoMark Limited which was acquired in March 2021. The test is expected to be commercialised in the next 6-12 months.

Des O’Leary, CEO of OncoAssure, said: “Along with our team of experienced biomarker development scientists and biostatisticians I am delighted to be involved in the establishment of OncoAssure. Using our focussed and validated approach we aim to be at the forefront of the development of new clinically important biomarkers that significantly improve cancer management and treatment”

You can keep up to date with us on Twitter @OncoAssure and Linkedin